Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190538 | 0.92 | HPGD (0.40) | EPHX2EPHX1HPGDPDGFRBP2RX7 | |
| SCHEMBL13532904 | 0.92 | HPGD (0.40) | EPHX2EPHX1HPGDPDGFRBP2RX7 | |
| SCHEMBL13532850 | 0.91 | HPGD (0.39) | EPHX2EPHX1HPGDPDGFRBP2RX7 | |
| SCHEMBL3193417 | 0.90 | P2RX7 (0.43) | EPHX2EPHX1P2RX7KDM5AKDM5B | |
| SCHEMBL13532756 | 0.90 | KDM5A (0.43) | EPHX2EPHX1P2RX7KDM5AKDM5B | |
| SCHEMBL4986071 | 0.88 | MEN1 (0.51) | EPHX2EPHX1HPGDPDGFRBP2RX7 | |
| SCHEMBL13532522 | 0.88 | HPGD (0.46) | EPHX2HPGDP2RX7KDM5AKDM5B | |
| SCHEMBL13532933 | 0.86 | EPHX2 (0.42) | EPHX2EPHX1HPGDPDGFRBP2RX7 | |
| SCHEMBL13532471 | 0.86 | P2RX7 (0.49) | HPGDP2RX7 | |
| SCHEMBL13532561 | 0.86 | GAA (0.42) | HPGDP2RX7KDM5AKDM5BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022531-A1 | NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022531-A1 | NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022531-A1 | NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2007028022-A2 | NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022531-A1 | NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | P2RX3, P2RX7, P2RX1 | EPHX2 1740/4885EPHX1 653/4885HPGD 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.